nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»10.31146/1682-8658-ecg-234-2-243-249nogr-3103Research ArticleОБЗОРREVIEWТегопразан - калий-конкурентный блокатор секреции соляной кислотыTegoprazan is a potassium-competitive blocker of hydrochloric acid secretionhttps://orcid.org/0000-0001-8736-5851ЛазебникЛ. Б.LazebnikL. B.leonid.borisl@gmail.comФедеральное государственное бюджетное образовательное учреждение высшего образования «Российский университет медицины» Министерства здравоохранения Российской ФедерацииРоссияRussian University of MedicineRussian Federation20253108202502243249Copyright © Лазебник Л.Б., 20252025Лазебник Л.Б.Lazebnik L.B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/3103

Калий-конкурентные блокаторы кислот (P-CAB), такие как тегопразан, представляют собой новый класс препаратов, которые могут полностью блокировать калий-связывающий сайт желудочной H+/K+ АТФазы, потенциально преодолевая ограничения ингибиторов протонной помпы (ИПП). Тегопразан разработан компанией CJ Healthcare (Республика Корея) для лечения гастроэзофагеальной рефлюксной болезни и инфекции Helicobacter pylori Тегопразан не зависим от метаболизма CYP2C19, что подчеркивает его значимость при принятии решения о трудно излечиваемых состояниях, таких как пептическая язва, рефрактерный гастроэзофагеальный рефлюкс, устойчивый к антибиотикам H. Pylori, особенно в некоторых регионах географических регионах. Высокая эффективность тегопразана при лечении ночных прорывов кислоты, при использовании его в 14-дневных схемах эрадикации совместно с висмутом, кларитромицином, рекомендуемых международными и национальными профессиональными сообществами. При сравнении эффективности и безопасности с различными ИПП и другими P-CAB, используемыми для лечения кислотозависимых заболеваний, тегопразан показывает незначительное количество легко переносимых и устранимых нежелательных побочных эффектов. Тегопразан демонстрирует быстрое начало действия, прямое действие на протонную помпу (без превращения в пролекарство), полное ее ингибирование начиная со стартовой дозы, высокую длительность терапевтического эффекта, профилактику ночного кислотного прорыва, может приниматься независимо от времени

Potassium-competitive acid blockers (P-CABs), such as tegoprazan, are a new class of drugs that can completely block the potassium-binding site of the gastric H+/K+ ATPase, potentially overcoming the limitations of proton pump inhibitors (PPIs). Tegoprazan was developed by CJ Healthcare (Republic of Korea) for the treatment of gastroesophageal reflux disease and Helicobacter pylori infection. Tegoprazan is independent of CYP2C19 metabolism, which emphasizes its importance in decision-making on difficult-to-treat conditions such as peptic ulcer, refractory gastroesophageal reflux, antibiotic-resistant H. Pylori, especially in some regions of the geographic regions. High efficiency of tegoprazan in the treatment of nocturnal acid breakthroughs, when used in 14-day eradication regimens together with bismuth, clarithromycin, recommended by international and national professional societies. When comparing the efficacy and safety with various PPIs and other P-CABs used to treat acid-related diseases, tegoprazan shows a small number of easily tolerated and eliminated undesirable side effects. Tegoprazan demonstrates a rapid onset of action, direct action on the proton pump (without turning into a prodrug), its complete inhibition starting from the starting dose, a high duration of the therapeutic effect, prevention of nocturnal acid breakthrough, can be taken regardless of meal time.

тегопразанкалий-конкурентные блокаторы соляной кислотыкислотозависимые заболеваниягастроэзофагеальный рефлюксгастроэзофагеальная рефлюксная болезньпептическая язва желудкаэрадикационная антихеликобактерная терапиярефрактерность к кларитромицинуночные кислотные прорывынестероидные противовосталительные препаратыингибиторы протонной помпыtegoprazanpotassium-competitive acid blockeracid-related diseasesgastroesophageal refluxgastroesophageal reflux diseasepeptic ulcereradication anti-Helicobacter therapyclarithromycin refractorinessnocturnal acid breakthroughsnonsteroidal anti-inflammatory drugsproton pump inhibitorsReferencesLindberg P., Brändström A., Wallmark B., Mattsson H., Rikner L., Hoffmann K.J. Omeprazole: the first proton pump inhibitor. Med Res Rev. 1990 Jan-Mar;10(1):1-54. doi: 10.1002/med.2610100102.Lindberg P., Brändström A., Wallmark B., Mattsson H., Rikner L., Hoffmann K.J. Omeprazole: the first proton pump inhibitor. Med Res Rev. 1990 Jan-Mar;10(1):1-54. doi: 10.1002/med.2610100102.Yibirin M., De Oliveira D., Valera R., Plitt A.E., Lutgen S. Adverse Effects Associated with Proton Pump Inhibitor Use. Cureus. 2021 Jan 18;13(1): e12759. doi: 10.7759/cureus.12759.Yibirin M., De Oliveira D., Valera R., Plitt A.E., Lutgen S. Adverse Effects Associated with Proton Pump Inhibitor Use. Cureus. 2021 Jan 18;13(1): e12759. doi: 10.7759/cureus.12759.Mössner J. The Indications, Applications, and Risks of Proton Pump Inhibitors. Dtsch Arztebl Int. 2016 Jul 11;113(27-28):477-83. doi: 10.3238/arztebl.2016.0477.Mössner J. The Indications, Applications, and Risks of Proton Pump Inhibitors. Dtsch Arztebl Int. 2016 Jul 11;113(27-28):477-83. doi: 10.3238/arztebl.2016.0477.Shabil M., Padhi B.K., Khatib M.N. et al. Risk of stroke associated with proton pump inhibitor use among individuals with and without pre-existing cardiovascular diseases: a systematic review and meta-analysis. J Cardiothorac Surg. 2025 Jan 29;20(1):107. doi: 10.1186/s13019-024-03161-4.Shabil M., Padhi B.K., Khatib M.N. et al. Risk of stroke associated with proton pump inhibitor use among individuals with and without pre-existing cardiovascular diseases: a systematic review and meta-analysis. J Cardiothorac Surg. 2025 Jan 29;20(1):107. doi: 10.1186/s13019-024-03161-4.Zeng R., Cheng Y., Luo D. et al.Comprehensive analysis of proton pump inhibitors and risk of digestive tract cancers. Eur J Cancer. 2021 Oct;156:190-201. doi: 10.1016/j.ejca.2021.07.030.Zeng R., Cheng Y., Luo D. et al.Comprehensive analysis of proton pump inhibitors and risk of digestive tract cancers. Eur J Cancer. 2021 Oct;156:190-201. doi: 10.1016/j.ejca.2021.07.030.Ivashkin V.T., Trukhmanov A.S., Maev I.V. et al. Diagnosis and Treatment of Gastroesophageal Reflux Disease (Clinical Guidelines of the Russian Gastroenterological Association, Russian Scientific Medical Society of Internal Medicine, Russian Society for the Prevention of Noncommunicable Diseases, Scientific Community for Human Microbiome Research).Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2024;34(5):111-135. doi: 10.22416/1382-4376-2024-34-5-111-135.@@ Ивашкин В.Т., Трухманов А.С., Маев И.В. и др. Диагностика и лечение гастроэзофагеальной рефлюксной болезни (Рекомендации Российской гастроэнтерологической ассоциации, Российского научного медицинского общества терапевтов, Российского общества профилактики неинфекционных заболеваний, Научного сообщества по изучению микробиома человека). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2024;34(5):111-135. doi: 10.22416/1382-4376-2024-34-5-111-135.Ivashkin V.T., Trukhmanov A.S., Maev I.V. et al. Diagnosis and Treatment of Gastroesophageal Reflux Disease (Clinical Guidelines of the Russian Gastroenterological Association, Russian Scientific Medical Society of Internal Medicine, Russian Society for the Prevention of Noncommunicable Diseases, Scientific Community for Human Microbiome Research).Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2024;34(5):111-135. doi: 10.22416/1382-4376-2024-34-5-111-135.@@ Ивашкин В.Т., Трухманов А.С., Маев И.В. и др. Диагностика и лечение гастроэзофагеальной рефлюксной болезни (Рекомендации Российской гастроэнтерологической ассоциации, Российского научного медицинского общества терапевтов, Российского общества профилактики неинфекционных заболеваний, Научного сообщества по изучению микробиома человека). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2024;34(5):111-135. doi: 10.22416/1382-4376-2024-34-5-111-135.Maev I.V., Andreev D.N., Samsonov A.A., Cheryomushkina A.S. Peptic ulcer: the current state of the problem. Meditsinskiy sovet = Medical Council. 2022;(6):100-108. (In Russ.) doi: 10.21518/2079-701X-2022-16-6-100-108.@@ Маев И.В., Андреев Д.Н., Самсонов А.А., Черёмушкина А.С. Язвенная болезнь: современное состояние проблемы. Медицинский Совет. 2022;(6):100-108. doi: 10.21518/2079-701X-2022-16-6-100-108.Maev I.V., Andreev D.N., Samsonov A.A., Cheryomushkina A.S. Peptic ulcer: the current state of the problem. Meditsinskiy sovet = Medical Council. 2022;(6):100-108. (In Russ.) doi: 10.21518/2079-701X-2022-16-6-100-108.@@ Маев И.В., Андреев Д.Н., Самсонов А.А., Черёмушкина А.С. Язвенная болезнь: современное состояние проблемы. Медицинский Совет. 2022;(6):100-108. doi: 10.21518/2079-701X-2022-16-6-100-108.Hunt R.H., Scarpignato C. Potent Acid Suppression with PPIs and P-CABs: What’s New? Curr Treat Options Gastroenterol. 2018 Dec;16(4):570-590. doi: 10.1007/s11938-018-0206-y.Hunt R.H., Scarpignato C. Potent Acid Suppression with PPIs and P-CABs: What’s New? Curr Treat Options Gastroenterol. 2018 Dec;16(4):570-590. doi: 10.1007/s11938-018-0206-y.Ortenberg E.A., Lyapina M.V., Dorodnyeva E.F.Competitive proton pump inhibitors - status and Prospects of use. Experimental and Clinical Gastroenterology. 2023;(4):86-92. (In Russ.) doi: 10.31146/1682-8658-ecg-212-4-86-92.@@ Ортенберг ЭА, Ляпина МВ, Дороднева ЕФ. Калий-конкурентные ингибиторы протонной помпы - состояние и перспективы использования. Экспериментальная и Клиническая Гастроэнтерология. 2023;(4):86-92. doi: 10.31146/1682-8658-ecg-212-4-86-92.Ortenberg E.A., Lyapina M.V., Dorodnyeva E.F.Competitive proton pump inhibitors - status and Prospects of use. Experimental and Clinical Gastroenterology. 2023;(4):86-92. (In Russ.) doi: 10.31146/1682-8658-ecg-212-4-86-92.@@ Ортенберг ЭА, Ляпина МВ, Дороднева ЕФ. Калий-конкурентные ингибиторы протонной помпы - состояние и перспективы использования. Экспериментальная и Клиническая Гастроэнтерология. 2023;(4):86-92. doi: 10.31146/1682-8658-ecg-212-4-86-92.DragBank. Tegoprazan [Internet]. [cited 2025 Mar 9]. Available from: https://go.drugbank.com/drugs/DB16690DragBank. Tegoprazan [Internet]. [cited 2025 Mar 9]. Available from: https://go.drugbank.com/drugs/DB16690Guo K., He X., Zhao H., Ma C. Characterisation of degradation products of tegoprazan by LC-MS and GC-MS. J Pharm Biomed Anal. 2023 May 10;228:115323. doi: 10.1016/j.jpba.2023.115323.Guo K., He X., Zhao H., Ma C. Characterisation of degradation products of tegoprazan by LC-MS and GC-MS. J Pharm Biomed Anal. 2023 May 10;228:115323. doi: 10.1016/j.jpba.2023.115323.Han S., Choi H.Y., Kim Y.H. et al. Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2019 Oct;50(7):751-9. doi: 10.1111/apt.15438.Han S., Choi H.Y., Kim Y.H. et al. Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2019 Oct;50(7):751-9. doi: 10.1111/apt.15438.Han S., Choi H.Y., Kim Y.H. et al. Effect of food on the pharmacokinetics and pharmacodynamics of a single oral dose of tegoprazan. Clin Ther. 2021 Aug;43(8):1371-1380. doi: 10.1016/j.clinthera.2021.06.007.Han S., Choi H.Y., Kim Y.H. et al. Effect of food on the pharmacokinetics and pharmacodynamics of a single oral dose of tegoprazan. Clin Ther. 2021 Aug;43(8):1371-1380. doi: 10.1016/j.clinthera.2021.06.007.Anik A.H., Proma F.A., Saha P., Sarker S. Tegoprazan as a New Remedy for Gastrointestinal Diseases in Comparison with its Therapeutic Predecessors: A Mini-Review. Curr Drug Res Rev. 2023 Apr 28. doi: 10.2174/2589977515666230428140741.Anik A.H., Proma F.A., Saha P., Sarker S. Tegoprazan as a New Remedy for Gastrointestinal Diseases in Comparison with its Therapeutic Predecessors: A Mini-Review. Curr Drug Res Rev. 2023 Apr 28. doi: 10.2174/2589977515666230428140741.Ngo L.T., Lee J., Yun H.Y., Chae J.W. Development of a Physiologically Based Pharmacokinetic Model for Tegoprazan: Application for the Prediction of Drug-Drug Interactions with CYP3A4 Perpetrators. Pharmaceutics. 2023 Jan 4;15(1):182. doi: 10.3390/pharmaceutics15010182.Ngo L.T., Lee J., Yun H.Y., Chae J.W. Development of a Physiologically Based Pharmacokinetic Model for Tegoprazan: Application for the Prediction of Drug-Drug Interactions with CYP3A4 Perpetrators. Pharmaceutics. 2023 Jan 4;15(1):182. doi: 10.3390/pharmaceutics15010182.Ghim J.L., Chin M.C., Jung J. et al. Pharmacokinetics and Pharmacodynamics of Tegoprazan Coadministered With Amoxicillin and Clarithromycin in Healthy Subjects. J Clin Pharmacol. 2021 Jul;61(7):913-922. doi: 10.1002/jcph.1805.Ghim J.L., Chin M.C., Jung J. et al. Pharmacokinetics and Pharmacodynamics of Tegoprazan Coadministered With Amoxicillin and Clarithromycin in Healthy Subjects. J Clin Pharmacol. 2021 Jul;61(7):913-922. doi: 10.1002/jcph.1805.Oh M., Lee H., Kim S., Kim B., Song G.S., Shin J.G., Ghim J.L. Evaluation of pharmacokinetic drug-drug interaction between tegoprazan and clarithromycin in healthy subjects. Transl Clin Pharmacol. 2023 Jun;31(2):114-123. doi: 10.12793/tcp.2023.31.e11.Oh M., Lee H., Kim S., Kim B., Song G.S., Shin J.G., Ghim J.L. Evaluation of pharmacokinetic drug-drug interaction between tegoprazan and clarithromycin in healthy subjects. Transl Clin Pharmacol. 2023 Jun;31(2):114-123. doi: 10.12793/tcp.2023.31.e11.Jeon J.Y., Kim S.Y., Moon S.J., Oh K., Lee J., Kim B., Song G.S., Kim M.G. Pharmacokinetic Interactions between Tegoprazan and Metronidazole/Tetracycline/Bismuth and Safety Assessment in Healthy Korean Male Subjects. Clin Ther. 2021 Apr;43(4):722-734. doi: 10.1016/j.clinthera.2021.01.026.Jeon J.Y., Kim S.Y., Moon S.J., Oh K., Lee J., Kim B., Song G.S., Kim M.G. Pharmacokinetic Interactions between Tegoprazan and Metronidazole/Tetracycline/Bismuth and Safety Assessment in Healthy Korean Male Subjects. Clin Ther. 2021 Apr;43(4):722-734. doi: 10.1016/j.clinthera.2021.01.026.Kim M.G., Im Y.J., Lee J.H., Kim E.Y., Yeom S.W., Kim J.S.Comparison of hepatotoxicity of tegoprazan, a novel potassium-competitive acid blocker, with proton pump inhibitors using real-world data: A nationwide cohort study. Front Med (Lausanne). 2023 Jan 11;9:1076356. doi: 10.3389/fmed.2022.1076356.Kim M.G., Im Y.J., Lee J.H., Kim E.Y., Yeom S.W., Kim J.S.Comparison of hepatotoxicity of tegoprazan, a novel potassium-competitive acid blocker, with proton pump inhibitors using real-world data: A nationwide cohort study. Front Med (Lausanne). 2023 Jan 11;9:1076356. doi: 10.3389/fmed.2022.1076356.Zheng H., Yuan S., Liu J. Efficacy and safety of tegoprazan in the treatment of gastroesophageal reflux disease: A protocol for meta-analysis and systematic review. PLoS One. 2024 May 2;19(5): e0302450. doi: 10.1371/journal.pone.0302450.Zheng H., Yuan S., Liu J. Efficacy and safety of tegoprazan in the treatment of gastroesophageal reflux disease: A protocol for meta-analysis and systematic review. PLoS One. 2024 May 2;19(5): e0302450. doi: 10.1371/journal.pone.0302450.Han S., Choi H.Y., Kim Y.H., Choi S., Kim S., Nam J.Y., Kim B., Song G.S., Lim H.S., Bae K.S.Comparison of Pharmacodynamics between Tegoprazan and Dexlansoprazole Regarding Nocturnal Acid Breakthrough: A Randomized Crossover Study. Gut Liver. 2023 Jan 15;17(1):92-99. doi: 10.5009/gnl220050.Han S., Choi H.Y., Kim Y.H., Choi S., Kim S., Nam J.Y., Kim B., Song G.S., Lim H.S., Bae K.S.Comparison of Pharmacodynamics between Tegoprazan and Dexlansoprazole Regarding Nocturnal Acid Breakthrough: A Randomized Crossover Study. Gut Liver. 2023 Jan 15;17(1):92-99. doi: 10.5009/gnl220050.Takahashi N., Take Y. Tegoprazan, a Novel Potassium-Competitive Acid Blocker to Control Gastric Acid Secretion and Motility. J Pharmacol Exp Ther. 2018 Feb;364(2):275-286. doi: 10.1124/jpet.117.244202.Takahashi N., Take Y. Tegoprazan, a Novel Potassium-Competitive Acid Blocker to Control Gastric Acid Secretion and Motility. J Pharmacol Exp Ther. 2018 Feb;364(2):275-286. doi: 10.1124/jpet.117.244202.Han S., Choi H.Y., Kim Y.H., Nam J.Y., Kim B., Song G.S., Lim H.S., Bae K.S. Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2019 Oct;50(7):751-759. doi: 10.1111/apt.15438.Han S., Choi H.Y., Kim Y.H., Nam J.Y., Kim B., Song G.S., Lim H.S., Bae K.S. Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2019 Oct;50(7):751-759. doi: 10.1111/apt.15438.Cho Y.K., Choi M.G., Choi S.C. et al. Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer. Aliment Pharmacol Ther. 2020 Sep;52(5):789-797. doi: 10.1111/apt.15865.Cho Y.K., Choi M.G., Choi S.C. et al. Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer. Aliment Pharmacol Ther. 2020 Sep;52(5):789-797. doi: 10.1111/apt.15865.Yang E., Kim S., Kim B. et al. Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole. Br J Clin Pharmacol. 2022 Jul;88(7):3288-3296. doi: 10.1111/bcp.15268.Yang E., Kim S., Kim B. et al. Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole. Br J Clin Pharmacol. 2022 Jul;88(7):3288-3296. doi: 10.1111/bcp.15268.Kim J.S., Seo S.I., Kang S.H. et al. Effects of Tegoprazan Versus Esomeprazole on Nighttime Heartburn and Sleep Quality in Gastroesophageal Reflux Disease: A Multicenter Double-blind Randomized Controlled Trial. J Neurogastroenterol Motil. 2023 Jan 30;29(1):58-64. doi: 10.5056/jnm22104.Kim J.S., Seo S.I., Kang S.H. et al. Effects of Tegoprazan Versus Esomeprazole on Nighttime Heartburn and Sleep Quality in Gastroesophageal Reflux Disease: A Multicenter Double-blind Randomized Controlled Trial. J Neurogastroenterol Motil. 2023 Jan 30;29(1):58-64. doi: 10.5056/jnm22104.Zong Y., Lan C., Li X. et al. Efficacy and safety of tegoprazan for duodenal ulcers in Chinese patients: a multicenter, randomized, double-blind, non-inferiority, phase III study. Curr Med Res Opin. 2024 Nov;40(11):1855-1862. doi: 10.1080/03007995.2024.2414090.Zong Y., Lan C., Li X. et al. Efficacy and safety of tegoprazan for duodenal ulcers in Chinese patients: a multicenter, randomized, double-blind, non-inferiority, phase III study. Curr Med Res Opin. 2024 Nov;40(11):1855-1862. doi: 10.1080/03007995.2024.2414090.Kim S.H., Cho K.B., Chun H.J. et al. Randomised clinical trial: comparison of tegoprazan and placebo in non-erosive reflux disease. Aliment Pharmacol Ther. 2021 Aug;54(4):402-411. doi: 10.1111/apt.16477.Kim S.H., Cho K.B., Chun H.J. et al. Randomised clinical trial: comparison of tegoprazan and placebo in non-erosive reflux disease. Aliment Pharmacol Ther. 2021 Aug;54(4):402-411. doi: 10.1111/apt.16477.Cho J.H., Jin S.Y., Park S.Comparison of tegoprazan and proton pump inhibitors for first-line Helicobacter pylori eradication: a systematic review with meta-analysis. Expert Rev Anti Infect Ther. 2025 Feb-Apr;23(2-4):227-233. doi: 10.1080/14787210.2025.2459722.Cho J.H., Jin S.Y., Park S.Comparison of tegoprazan and proton pump inhibitors for first-line Helicobacter pylori eradication: a systematic review with meta-analysis. Expert Rev Anti Infect Ther. 2025 Feb-Apr;23(2-4):227-233. doi: 10.1080/14787210.2025.2459722.Jin T., Wu W., Zhang L., Xuan H., Zhang H., Zhong L. The efficacy and safety of Vonoprazan and Tegoprazan in Helicobacter pylori eradication: a comprehensive systematic review and meta-analysis of randomized controlled trials. Therap Adv Gastroenterol. 2025 Jan 31;18:17562848251314801. doi: 10.1177/17562848251314801.Jin T., Wu W., Zhang L., Xuan H., Zhang H., Zhong L. The efficacy and safety of Vonoprazan and Tegoprazan in Helicobacter pylori eradication: a comprehensive systematic review and meta-analysis of randomized controlled trials. Therap Adv Gastroenterol. 2025 Jan 31;18:17562848251314801. doi: 10.1177/17562848251314801.Simadibrata D.M., Lesmana E., Damara I. et al. Tegoprazan-Containing Versus Proton Pump Inhibitor-Containing Therapy for First-Line Eradication of Helicobacter pylori: A Meta-Analysis of Randomized Controlled Trials. JGH Open. 2025 Mar 12;9(3): e70134. doi: 10.1002/jgh3.70134.Simadibrata D.M., Lesmana E., Damara I. et al. Tegoprazan-Containing Versus Proton Pump Inhibitor-Containing Therapy for First-Line Eradication of Helicobacter pylori: A Meta-Analysis of Randomized Controlled Trials. JGH Open. 2025 Mar 12;9(3): e70134. doi: 10.1002/jgh3.70134.Choi Y.J., Lee Y.C., Kim J.M. et al. Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial. Gut Liver. 2022 Jul 15;16(4):535-546. doi: 10.5009/gnl220055.Choi Y.J., Lee Y.C., Kim J.M. et al. Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial. Gut Liver. 2022 Jul 15;16(4):535-546. doi: 10.5009/gnl220055.Lee J.W., Kim N., Nam R.H., Yu J.E., Son J.H., Lee S.M., Lee D.H. Efficacy of Tegoprazan for Improving the Susceptibility of Antimicrobial Agents against Antibiotic-Resistant Helicobacter pylori. Gut Liver. 2021 Jan 15;15(1):53-60. doi: 10.5009/gnl20247.Lee J.W., Kim N., Nam R.H., Yu J.E., Son J.H., Lee S.M., Lee D.H. Efficacy of Tegoprazan for Improving the Susceptibility of Antimicrobial Agents against Antibiotic-Resistant Helicobacter pylori. Gut Liver. 2021 Jan 15;15(1):53-60. doi: 10.5009/gnl20247.Lee J. Role of Tegoprazan in Helicobacter pylori Eradication Therapy. Gut Liver. 2022 Jul 15;16(4):493-494. doi: 10.5009/gnl220272.Lee J. Role of Tegoprazan in Helicobacter pylori Eradication Therapy. Gut Liver. 2022 Jul 15;16(4):493-494. doi: 10.5009/gnl220272.Jung Y.S., Kim S., Kim H.Y., Noh S.J., Park J.H., Park C.H. 7-day versus 14-day tegoprazan-based triple therapy to treat Helicobacter pylori infection: Real-world evidence. J Gastroenterol Hepatol. 2022 Oct;37(10):1911-1918. doi: 10.1111/jgh.15939.Jung Y.S., Kim S., Kim H.Y., Noh S.J., Park J.H., Park C.H. 7-day versus 14-day tegoprazan-based triple therapy to treat Helicobacter pylori infection: Real-world evidence. J Gastroenterol Hepatol. 2022 Oct;37(10):1911-1918. doi: 10.1111/jgh.15939.Kang S., Kim N.H., Jeong S., Kim J.W., Moon J.R., Lee Y.S., Son J.H.Comparison of Tegoprazan- and Lansoprazole-Based Fourteen-Day Triple Therapies as First-Line Treatments for Helicobacter pylori Eradication. Korean J Helicobacter Up Gastrointest Res. 2024 Jun;24(2):168-174. doi: 10.7704/kjhugr.2024.0012.Kang S., Kim N.H., Jeong S., Kim J.W., Moon J.R., Lee Y.S., Son J.H.Comparison of Tegoprazan- and Lansoprazole-Based Fourteen-Day Triple Therapies as First-Line Treatments for Helicobacter pylori Eradication. Korean J Helicobacter Up Gastrointest Res. 2024 Jun;24(2):168-174. doi: 10.7704/kjhugr.2024.0012.Jung Y.S., Jung B.W., Park C.H.Comparative efficacy of Helicobacter pylori eradication therapy between tegoprazan-based concomitant and bismuth quadruple therapies: A real-world evidence. J Gastroenterol Hepatol. 2025 Jan;40(1):159-165. doi: 10.1111/jgh.16798.Jung Y.S., Jung B.W., Park C.H.Comparative efficacy of Helicobacter pylori eradication therapy between tegoprazan-based concomitant and bismuth quadruple therapies: A real-world evidence. J Gastroenterol Hepatol. 2025 Jan;40(1):159-165. doi: 10.1111/jgh.16798.Cho J.H. Bismuth add-on improves the efficacy of 2-week tegoprazan-based triple therapy for first-line Helicobacter pylori eradication: a real-world evidence study. Expert Rev Anti Infect Ther. 2024 Sep;22(9):793-799. doi: 10.1080/14787210.2024.2329251.Cho J.H. Bismuth add-on improves the efficacy of 2-week tegoprazan-based triple therapy for first-line Helicobacter pylori eradication: a real-world evidence study. Expert Rev Anti Infect Ther. 2024 Sep;22(9):793-799. doi: 10.1080/14787210.2024.2329251.Park C.H., Song M.J., Jung B.W., Park J.H., Jung Y.S.Comparative Efficacy of 14-Day Tegoprazan-Based Triple vs. 10-Day Tegoprazan-Based Concomitant Therapy for Helicobacter pylori Eradication. J Pers Med. 2022 Nov 17;12(11):1918. doi: 10.3390/jpm12111918.Park C.H., Song M.J., Jung B.W., Park J.H., Jung Y.S.Comparative Efficacy of 14-Day Tegoprazan-Based Triple vs. 10-Day Tegoprazan-Based Concomitant Therapy for Helicobacter pylori Eradication. J Pers Med. 2022 Nov 17;12(11):1918. doi: 10.3390/jpm12111918.Kim J.S., Ko W., Chung J.W., Kim T.H. Efficacy of tegoprazan-based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: A randomized, double-blind, active-controlled study. Helicobacter. 2023 Jun;28(3): e12977. doi: 10.1111/hel.12977.Kim J.S., Ko W., Chung J.W., Kim T.H. Efficacy of tegoprazan-based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: A randomized, double-blind, active-controlled study. Helicobacter. 2023 Jun;28(3): e12977. doi: 10.1111/hel.12977.Moon S.J., Shin N., Kang M., Kim B., Kim M.G. Pharmacokinetic Interactions Between Tegoprazan and Naproxen, Aceclofenac, and Celecoxib in Healthy Korean Male Subjects. Clin Ther. 2022 Jul;44(7):930-944.e1. doi: 10.1016/j.clinthera.2022.06.002.Moon S.J., Shin N., Kang M., Kim B., Kim M.G. Pharmacokinetic Interactions Between Tegoprazan and Naproxen, Aceclofenac, and Celecoxib in Healthy Korean Male Subjects. Clin Ther. 2022 Jul;44(7):930-944.e1. doi: 10.1016/j.clinthera.2022.06.002.Lee H.J., Moon J.W., Koh S.J., Im J.P., Kim B.G., Kim J.S. Effect of tegoprazan, a novel potassium-competitive acid blocker, on non-steroidal anti-inflammatory drug (NSAID)-induced enteropathy. Sci Rep. 2024 Nov 8;14(1):27173. doi: 10.1038/s41598-024-78581-2.Lee H.J., Moon J.W., Koh S.J., Im J.P., Kim B.G., Kim J.S. Effect of tegoprazan, a novel potassium-competitive acid blocker, on non-steroidal anti-inflammatory drug (NSAID)-induced enteropathy. Sci Rep. 2024 Nov 8;14(1):27173. doi: 10.1038/s41598-024-78581-2.Son M., Park I.S., Kim S. et al. Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function. Front Immunol. 2022 May 25;13:870817. doi: 10.3389/fimmu.2022.870817.Son M., Park I.S., Kim S. et al. Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function. Front Immunol. 2022 May 25;13:870817. doi: 10.3389/fimmu.2022.870817.Kim B.W., Park J.J., Moon H.S. et al. The Effect of Tegoprazan on the Treatment of Endoscopic Resection-Induced Artificial Ulcers: A Multicenter, Randomized, Active-Controlled Study. Gut Liver. 2024 Mar 15; 18(2):257-264. doi: 10.5009/gnl230242.Kim B.W., Park J.J., Moon H.S. et al. The Effect of Tegoprazan on the Treatment of Endoscopic Resection-Induced Artificial Ulcers: A Multicenter, Randomized, Active-Controlled Study. Gut Liver. 2024 Mar 15; 18(2):257-264. doi: 10.5009/gnl230242.Baik G.H. et al.Comparison of rebamipide and tegoprazan combination therapy and tegoprazan monotherapy on the healing of endoscopic submucosal dissection-induced gastric ulcer: A randomized-controlled multicenter study. Endoscopy. 2025;57(S 02): С. OP140. doi: 10.1055/s-0045-1805246.Baik G.H. et al.Comparison of rebamipide and tegoprazan combination therapy and tegoprazan monotherapy on the healing of endoscopic submucosal dissection-induced gastric ulcer: A randomized-controlled multicenter study. Endoscopy. 2025;57(S 02): С. OP140. doi: 10.1055/s-0045-1805246.Cho Y.K., Kim J.H., Kim H.S. et al. Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis. Aliment Pharmacol Ther. 2023 Jan;57(1):72-80. doi: 10.1111/apt.17255.Cho Y.K., Kim J.H., Kim H.S. et al. Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis. Aliment Pharmacol Ther. 2023 Jan;57(1):72-80. doi: 10.1111/apt.17255.Hussaini H., Kebede T.M., Afework T.S., Kumari D., Fadeyi O., Chaudhari S.S., Habib I., Hirani S.Comparative Efficacy and Safety of Tegoprazan Versus Proton Pump Inhibitors for Erosive Esophagitis: A Systematic Review and Meta-Analysis. Cureus. 2025 May 1;17(5): e83302. doi: 10.7759/cureus.83302.Hussaini H., Kebede T.M., Afework T.S., Kumari D., Fadeyi O., Chaudhari S.S., Habib I., Hirani S.Comparative Efficacy and Safety of Tegoprazan Versus Proton Pump Inhibitors for Erosive Esophagitis: A Systematic Review and Meta-Analysis. Cureus. 2025 May 1;17(5): e83302. doi: 10.7759/cureus.83302.Shin C.M., Choi S.C., Cho J.W. et al.Comparison of Tegoprazan and Lansoprazole in Patients With Erosive Esophagitis up to 4 Weeks: A Multi-Center, Randomized, Double-Blind, Active-Comparator Phase 4 Trial. Neurogastroenterol Motil. 2025 Jan;37(1): e14969. doi: 10.1111/nmo.14969.Shin C.M., Choi S.C., Cho J.W. et al.Comparison of Tegoprazan and Lansoprazole in Patients With Erosive Esophagitis up to 4 Weeks: A Multi-Center, Randomized, Double-Blind, Active-Comparator Phase 4 Trial. Neurogastroenterol Motil. 2025 Jan;37(1): e14969. doi: 10.1111/nmo.14969.Zhu H., Xue Q., Song Y. et al. Efficacy and safety of tegoprazan (LXI-15028) vs. esomeprazole in patients with erosive esophagitis: A multicenter, randomized, double-blind, non-inferiority phase III trial. Chin Med J (Engl). 2024 Oct 30. doi: 10.1097/CM9.0000000000003276.Zhu H., Xue Q., Song Y. et al. Efficacy and safety of tegoprazan (LXI-15028) vs. esomeprazole in patients with erosive esophagitis: A multicenter, randomized, double-blind, non-inferiority phase III trial. Chin Med J (Engl). 2024 Oct 30. doi: 10.1097/CM9.0000000000003276.Jeon H.K., Kim G.H., Cheon Y.I., Shin S.C., Lee B.J. Efficacy of Tegoprazan in Patients with Laryngopharyngeal Reflux Disease: A Preliminary Feasibility Study. J Clin Med. 2023 Sep 22;12(19):6116. doi: 10.3390/jcm12196116.Jeon H.K., Kim G.H., Cheon Y.I., Shin S.C., Lee B.J. Efficacy of Tegoprazan in Patients with Laryngopharyngeal Reflux Disease: A Preliminary Feasibility Study. J Clin Med. 2023 Sep 22;12(19):6116. doi: 10.3390/jcm12196116.Lee S.K. The effect of potassium-competitive acid blocker tegoprazan on gastric cancer cells. 2023.Lee S.K. The effect of potassium-competitive acid blocker tegoprazan on gastric cancer cells. 2023.Piyush Agarwal, Brajesh Kumar Jha, Jaganmohan Somagoni, Sanjana Dawra, Sanketh Kumar Chakilam, Swarup Rajendra Wani, Rupa Banerjee, Rakesh Patel, Ravi Shankar, Geun Seog Song; Efficacy and Safety of Tegoprazan in Patients with Erosive Gastroesophageal Reflux Disease - A Multi-country, Prospective, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study. Japanese Journal of Gastroenterology. 2025 June; 11(1). doi: 10.52338/jjogastro.2025.4829.Piyush Agarwal, Brajesh Kumar Jha, Jaganmohan Somagoni, Sanjana Dawra, Sanketh Kumar Chakilam, Swarup Rajendra Wani, Rupa Banerjee, Rakesh Patel, Ravi Shankar, Geun Seog Song; Efficacy and Safety of Tegoprazan in Patients with Erosive Gastroesophageal Reflux Disease - A Multi-country, Prospective, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study. Japanese Journal of Gastroenterology. 2025 June; 11(1). doi: 10.52338/jjogastro.2025.4829.

The authors declare that there are no conflicts of interest present.